Ken Griffin Biotechnology

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
ETON
Eton Pharmaceuticals, Inc.
CALL
$564,000
42.9K
Q1 2024
Reduced 99.35%
CRNX
Crinetics Pharmaceuticals, Inc.
CALL
$562,000
11K
Q4 2024
Reduced 96.51%
NRIX
Nurix Therapeutics, Inc.
CALL
$561,000
29.8K
Q4 2024
Reduced 44.39%
CRDF
Cardiff Oncology, Inc.
CALL
$555,000
128K
Q4 2024
Added 37.21%
SNDX
Syndax Pharmaceuticals Inc
PUT
$545,000
41.3K
Q4 2024
Added 3103.42%
DYN
Dyne Therapeutics, Inc.
CALL
$539,000
22.9K
Q4 2024
Reduced 2.65%
PSTX
Poseida Therapeutics, Inc.
PUT
$532,000
55.5K
Q4 2024
New holding
AMLX
Amylyx Pharmaceuticals, Inc.
CALL
$508,000
135K
Q4 2024
Added 3.75%
ABCL
Ab Cellera Biologics Inc.
PUT
$504,000
172K
Q4 2024
Reduced 60.17%
LGND
Ligand Pharmaceuticals Inc
PUT
$503,000
4.7K
Q3 2024
Reduced 48.02%
HRMY
Harmony Biosciences Holdings, Inc.
CALL
$467,000
13.6K
Q4 2024
Added 784.58%
PRTA
Prothena Corp Public LTD CO
CALL
$465,000
33.6K
Q4 2024
Reduced 82.53%
ROIV
Roivant Sciences Ltd.
CALL
$457,000
38.7K
Q4 2024
Reduced 69.56%
ANNX
Annexon, Inc.
PUT
$454,000
88.5K
Q4 2024
Added 345.16%
ARCT
Arcturus Therapeutics Holdings Inc.
CALL
$449,000
26.5K
Q4 2024
Reduced 81.97%
AKRO
Akero Therapeutics, Inc.
CALL
$439,000
15.8K
Q4 2024
Added 803.86%
GLPG
Galapagos Nv
PUT
$431,000
15.7K
Q4 2024
Reduced 14.84%
ALDX
Aldeyra Therapeutics, Inc.
CALL
$422,000
84.6K
Q4 2024
Added 58.15%
JANX
Janux Therapeutics, Inc.
CALL
$422,000
7.9K
Q4 2024
Added 34.77%
TERN
Terns Pharmaceuticals, Inc.
PUT
$421,000
75.6K
Q4 2024
Reduced 11.04%
GLUE
Monte Rosa Therapeutics, Inc.
CALL
$420,000
60.6K
Q4 2024
Reduced 32.84%
KMPH
Kempharm, Inc
CALL
$415,000
84.1K
Q4 2024
Reduced 96.33%
IMCR
Immunocore Holdings PLC
CALL
$413,000
14K
Q4 2024
Added 28.02%
ARQT
Arcutis Biotherapeutics, Inc.
PUT
$399,000
28.7K
Q4 2024
Reduced 97.06%
VERV
Verve Therapeutics, Inc.
PUT
$397,000
70.5K
Q4 2024
Reduced 82.66%
DNLI
Denali Therapeutics Inc.
CALL
$395,000
19.4K
Q4 2024
Added 6.77%
CMRX
Chimerix Inc
CALL
$393,000
113K
Q4 2024
Reduced 31.56%
VCYT
Veracyte, Inc.
CALL
$388,000
9.8K
Q4 2024
Reduced 40.8%
CRDF
Cardiff Oncology, Inc.
PUT
$388,000
89.6K
Q4 2024
Added 37.21%
CRNX
Crinetics Pharmaceuticals, Inc.
PUT
$388,000
7.6K
Q4 2024
Reduced 96.51%
CCCC
C4 Therapeutics, Inc.
PUT
$371,000
103K
Q4 2024
Reduced 16.07%
ARVN
Arvinas, Inc.
CALL
$366,000
19.1K
Q4 2024
Added 13.49%
ABCL
Ab Cellera Biologics Inc.
CALL
$359,000
123K
Q4 2024
Reduced 60.17%
RCKT
Rocket Pharmaceuticals, Inc.
CALL
$349,000
27.8K
Q4 2024
Added 91.93%
RGNX
Regenxbio Inc.
CALL
$348,000
45.1K
Q4 2024
Added 188.05%
ZLAB
Zai Lab LTD
CALL
$348,000
13.3K
Q4 2024
Reduced 86.53%
ATAI
Atai Life Sciences N.V.
CALL
$341,000
257K
Q4 2024
New holding
MREO
Mereo Biopharma Group PLC
PUT
$340,000
97.3K
Q4 2024
Added 141.02%
PTGX
Protagonist Therapeutics, Inc
CALL
$339,000
8.8K
Q4 2024
Added 3163.34%
RCUS
Arcus Biosciences, Inc.
PUT
$336,000
22.6K
Q4 2024
Added 13.44%
MRVI
Maravai Lifesciences Holdings, Inc.
CALL
$329,000
60.5K
Q4 2024
New holding
GMAB
Genmab A/S
CALL
$327,000
15.7K
Q4 2024
Added 137.88%
FOLD
Amicus Therapeutics, Inc.
PUT
$326,000
34.7K
Q4 2024
Added 126.99%
ABSI
Absci Corp
PUT
$321,000
123K
Q4 2024
New holding
ALDX
Aldeyra Therapeutics, Inc.
PUT
$321,000
64.5K
Q4 2024
Added 58.15%
KURA
Kura Oncology, Inc.
PUT
$321,000
36.9K
Q4 2024
Reduced 16.99%
COGT
Cogent Biosciences, Inc.
CALL
$314,000
40.3K
Q4 2024
Added 912.37%
AVTE
Aerovate Therapeutics, Inc.
CALL
$311,000
118K
Q4 2024
New holding
KALV
Kal Vista Pharmaceuticals, Inc.
PUT
$310,000
36.6K
Q4 2024
Added 7.26%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email